Abstract:Tim Bothe, 1 Anne-Katrin Fietz, 2 Elke Schaeffner, 1 Antonios Douros, 3– 5 Anna Pöhlmann, 2 Nina Mielke, 1 Cédric Villain, 1, 6 Muhammad Helmi Barghouth, 1 Volker Wenning, 7 Natalie Ebert 1 1 Institute of Public Health, Charité – Universitätsmedizin Berlin, Berlin, Germany; 2 Institute of Biometry and Clinical Epidemiology, Charité – Universitätsmedizin Berlin, Berlin, Germany; 3 Departments of Medicine and of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada; 4 Institute of Clinical Pharmacology and Toxicology, Charité – Universitätsmedizin Berlin, Berlin, Germany; 5 Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada; 6 Normandie Univ UNICAEN, INSERM U1075 COMETE, service de Gériatrie, CHU de Caen, Caen, France; 7 AOK Nordost – Die Gesundheitskasse, Potsdam, Germany Correspondence: Tim Bothe, Charité – Universitätsmedizin Berlin, Institute of Public Health, Charitéplatz 1, Berlin, DE-10117, Germany, Tel +49 30 450 570054, Email Purpose: The validity of ICD-10 diagnostic codes for chronic kidney disease (CKD) in health claims data has not been sufficiently studied in the general population and over time. Patients and Methods: We used data from the Berlin Initiative Study (BIS), a prospective longitudinal cohort of community-dwelling individuals aged ≥ 70 years in Berlin, Germany. With estimated glomerular filtration rate (eGFR) as reference, we assessed the diagnostic validity (sensitivity, specificity, positive [PPV], and negative predictive values [NPV]) of different claims-based ICD-10 codes for CKD stages G3-5 (eGFR < 60mL/min/1.73m2: ICD-10 N18.x-N19), G3 (eGFR 30–< 60mL/min/1.73m2: N18.3), and G4-5 (eGFR < 30mL/min/1.73m2: N18.4– 5). We analysed trends over five study visits (2009– 2019). Results: We included data of 2068 participants at baseline (2009– 2011) and 870 at follow-up 4 (2018– 2019), of whom 784 (38.9%) and 440 (50.6%) had CKD G3-5, respectively. At baseline, sensitivity for CKD in claims data ranged from 0.25 (95%-confidence interval [CI] 0.22– 0.28) to 0.51 (95%-CI 0.48– 0.55) for G3-5, depending on the included ICD-10 codes, 0.20 (95%-CI 0.18– 0.24) for G3, and 0.36 (95%-CI 0.25– 0.49) for G4-5. Over the course of 10 years, sensitivity increased by 0.17 to 0.29 in all groups. Specificity, PPVs, and NPVs remained mostly stable over time and ranged from 0.82– 0.99, 0.47– 0.89, and 0.66– 0.98 across all study visits, respectively. Conclusion: German claims data showed overall agreeable performance in identifying older adults with CKD, while differentiation between stages was limited. Our results suggest increasing sensitivity over time possibly attributable to improved CKD diagnosis and awareness. Keywords: CKD, diagnostic validity, health claims data, sensitivity, specificity Health claims data have been recognized as a relevant data source and used increasingly in clinical and epidemiological studies over the past years as they reflect real-world clinical practice and health care for a large number of individuals. 1–3 Claims data have also been used for estimating the prevalence of chronic kidney disease (CKD) and associated adverse outcomes. 4–9 CKD is globally recognized as a relevant public health burden due to increased morbidity, 10,11 risk of hospitalizations, 12,13 vulnerability to infection, 14 high costs, 7,8 and mortality. 11,15,16 Its prevalence is estimated to range from 23% to 36% in persons aged ≥65 years, 17 or even higher in persons ≥80 years, 18 and expected to further increase due to ageing populations. 10,19 Despite their potential, claims data should be used cautiously when aiming to reliably identify patients with CKD given their lack of laboratory values. Several studies, including two systematic reviews from 2011, 20,21 evaluated the validity of CKD diagnostic codes and reported mostly poor sensitivity and limited generalisability of their findings. Sensitivity ranged from 3% to 88%, whereas specificity was overall high. 20–28 However, broadly diverging sensitivity estimates as well as differences among countries and health care systems limit generalisability. 20 Furthermore, many of the existing studies were based on samples with an indication for CKD assessment (eg, after hospitalization or in high risk populations) and used cross-sectional older inpatient data. Up to date, the diagnostic validity for CKD has not been sufficiently studied in the general population (ie, p -Abstract Truncated-

Validity of a Claims-Based Diagnosis of Obesity Among Medicare Beneficiaries

Applying machine learning approaches for predicting obesity risk using US health administrative claims database

Assessing the Comorbidity Gap Between Clinical Studies and Prevalence in Elderly Patient Populations.

Diagnostic rate estimation from Medicare records: Dependence on claim numbers and latent clinical features

Stratified Probabilistic Bias Analysis for Body Mass Index-related Exposure Misclassification in Postmenopausal Women

Identifying Dementia Severity Among People Living With Dementia Using Administrative Claims Data

Validation of a Description of Sarcopenic Obesity Defined As Excess Adiposity and Low Lean Mass Relative to Adiposity.

Development and validation of a claims-based prediction model for COPD severity.

Comparison of ICD code-based diagnosis of obesity with measured obesity in children and the implications for health care cost estimates

External Validation of an Electronic Phenotyping Algorithm Detecting Attention to High Body Mass Index in Pediatric Primary Care

A comparison of dementia diagnoses and cognitive function measures in Medicare claims and the Minimum Data Set

Factors associated with receiving an obesity diagnosis and obesity-related treatment for patients with obesity class II and III within a single integrated health system

Using a newly validated algorithm to estimate prevalence and incidence of Alzheimer’s Disease and related dementias in Medicare claims

Validation of self-reported height and weight in a large, nationwide cohort of U.S. adults

Patients with Newly Diagnosed Carcinoma of the Breast: Validation of a Claim-based Identification Algorithm

Development and Validation of Claims-Based Definitions to Identify Incident and Prevalent Inflammatory Bowel Disease in Administrative Healthcare Databases

Prevalence of spine degeneration diagnosis by type, age, gender, and obesity using Medicare data

Assessing the use of prescription drugs and dietary supplements in obese respondents in the National Health and Nutrition Examination Survey

Validating claims-based algorithms for a systemic lupus erythematosus diagnosis in Medicare data for informed use of the Lupus Index: a tool for geospatial research

Validity of Self-Reported Diabetes among Middle-Aged and Older Chinese Adults: the China Health and Retirement Longitudinal Study

Diagnostic Validity of Chronic Kidney Disease in Health Claims Data Over Time: Results from a Cohort of Community-Dwelling Older Adults in Germany